Abstract
Bone metastasis is a common phenomenon in patients with advanced prostate cancer. The molecular and cellular mechanisms involved in this process are not well understood. Past reviews on this subject primarily focused on prostate tumor growth in the bone marrow and the effects this growth has on bone homeostasis (ie osteoblastic and osteolytic). Cell chemotaxis and adhesion are also important for site-specific metastasis. In this review we have focused on chemotactic and cell adhesion molecules potentially involved in prostate cancer metastasis to bone. In addition, recently developed animal models for prostate cancer metastasis to bone are discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cooper, C., Pienta, K. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis 3, 6–12 (2000). https://doi.org/10.1038/sj.pcan.4500387
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500387
Keywords
This article is cited by
-
Current methods for studying metastatic potential of tumor cells
Cancer Cell International (2022)
-
DNA methylation silences miR-132 in prostate cancer
Oncogene (2013)
-
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium
Investigational New Drugs (2011)
-
Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis
Clinical & Experimental Metastasis (2008)
-
RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility
Oncogene (2006)